TITLE

Baxter Receives Marketing Authorization in European Union for VEPACEL Pre- Pandemic Influenza Vaccine

PUB. DATE
March 2012
SOURCE
Biomedical Market Newsletter;3/7/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the marketing authorization of pre-pandemic influenza vaccine VEPACEL of Baxter International Inc. has been granted by the European Commission (EC). It is mentioned that the vaccine has been made with the use of Vero cell technology in which natural influenza virus is allowed to be used.
ACCESSION #
75436304

 

Related Articles

  • BAXTER GETS CONTRACT FROM U.K. NHS FOR H5N1 FLU VACCINE.  // Worldwide Biotech;Apr2006, Vol. 18 Issue 4, p8 

    Reports on the contract from the National Health Service in Great Britain received by the European subsidiary of Baxter International Inc. to produce a stockpile of candidate H5N1 influenza vaccine based on an avian strain. Terms of the contract; Remarks from Joy Amundson, corporate vice...

  • Pharma: Other News To Note.  // BioWorld Today;3/5/2012, Vol. 23 Issue 43, p7 

    The article reports on the marketing authorization granted by the European Commission for Vepacel, a pre-pandemic influenza vaccine from Baxter International Inc.

  • U.S. drug maker's new Czech plant to make vaccine. Kirkland, Joel // Prague Business Journal;3/18/2002, Vol. 7 Issue 11, p3 

    Focuses on the production of flu vaccine by Baxter International Inc. in Prague, Czech Republic. Production of InfluJect, flu vaccine; Purchase of Sevac by Baxter; Advantage of the vaccine.

  • Influenza Vaccine 1980-1981.  // Annals of Internal Medicine;Sep80, Vol. 93 Issue 3, p466 

    Presents an annual revision of influenza vaccine recommendations in the U.S. as of 1980. Predominant strain of influenza virus in the U.S. during 1979 to 1980; Subtypes of influenza A on the basis of two antigens; General recommendations for vaccine use; Influenza vaccine available from 1980 to...

  • Immunization against Influenza: Comparison of Various Topical and Parenteral Regimens Containing Inactivated and/or Live Attenuated Vaccines in Healthy Adults. Keitel, Wendy A.; Cate, Thomas R.; Couch, Robert B.; Nino, Diane; Huggins, Linda L.; Six, Howard R.; Quarles, John M. // Journal of Infectious Diseases;1/15/2001, Vol. 183 Issue 2, p329 

    Provides information on a study which evaluated intranasal immunization with monovalent, live attenuated, cold-adapted recombinant or inactivated influenza virus (MIV) vaccine and intramuscular immunization with MIV. Information on influenza; Materials and methods used; Results; Conclusions.

  • Advances in the development of influenza virus vaccines. Krammer, Florian; Palese, Peter // Nature Reviews Drug Discovery;Apr2015, Vol. 14 Issue 4, p294 

    A correction to the article "Advances in the development of influenza virus vaccines" which appeared in a 2015 issue is presented.

  • Erratum to: Influenza A viruses: why focusing on M2e-based universal vaccines. Ebrahimi, Seyyed Mahmoud; Tebianian, Majid // Virus Genes;Feb2011, Vol. 42 Issue 1, p9 

    A correction to the article "Influenza A Viruses: Why Focusing on M2e-Based Universal Vaccines" that was published in the March 18, 2011 online issue is presented.

  • Studies on the IgA-independent immunological responses in mice to influenza virus challenge after oral vaccination with irradiated whole virus and an erythrocyte complex. Lidbury, Brett A; Grissell, Terrence V; Sizer, Philip J; Clancy, Robert; Cripps, Allan W // Immunology & Cell Biology;Apr2000, Vol. 78 Issue 2, p149 

    SummaryPrevious studies have described an oral influenza vaccine comprising whole irradiated virus and an erythrocyte complex (IV-EC), which gave broad-based protection against influenza virus challenge in mice. The present study examined the immune responses generated after live virus challenge...

  • Recommended composition of influenza virus vaccines for use in the 2002-2003 season.  // Weekly Epidemiological Record;2/22/2002, Vol. 77 Issue 8, p62 

    Presents updates on influenza activities worldwide as of February 2002. Influenza activities from October 2001 to February 2002; Outbreaks of influenza A and B in several countries; Antigenic characteristics of isolates; Studies with inactivated influenza virus vaccines; Recommendations for the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics